Published in Immunity on November 06, 2014
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med (2015) 1.98
CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat Immunol (2015) 1.73
Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
STING: infection, inflammation and cancer. Nat Rev Immunol (2015) 1.12
Innate immune recognition of DNA: A recent history. Virology (2015) 1.10
Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature (2017) 1.09
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06
Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. Cell Rep (2015) 1.03
DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep (2015) 1.01
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol (2016) 0.98
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A (2015) 0.97
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol (2016) 0.96
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat Cell Biol (2017) 0.94
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
Activation and regulation of DNA-driven immune responses. Microbiol Mol Biol Rev (2015) 0.92
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92
The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol (2015) 0.91
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother (2015) 0.90
Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. Cancer Res (2015) 0.89
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
Akt Kinase-Mediated Checkpoint of cGAS DNA Sensing Pathway. Cell Rep (2015) 0.89
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine (2015) 0.89
Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology (2015) 0.88
Immunotherapy and tumor microenvironment. Cancer Lett (2015) 0.88
Ancient Origin of cGAS-STING Reveals Mechanism of Universal 2',3' cGAMP Signaling. Mol Cell (2015) 0.87
PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res (2016) 0.87
Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells. Cancer Res (2016) 0.87
Innate immune signaling and regulation in cancer immunotherapy. Cell Res (2016) 0.86
Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. Transl Oncol (2016) 0.84
Interferons and the Immunogenic Effects of Cancer Therapy. Trends Immunol (2015) 0.84
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep (2016) 0.83
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. Front Oncol (2016) 0.83
STING Requires the Adaptor TRIF to Trigger Innate Immune Responses to Microbial Infection. Cell Host Microbe (2016) 0.83
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Cancer Res (2016) 0.83
The host STING pathway at the interface of cancer and immunity. J Clin Invest (2016) 0.83
The emerging roles of the STING adaptor protein in immunity and diseases. Immunology (2015) 0.82
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res (2015) 0.81
Upregulated LINE-1 Activity in the Fanconi Anemia Cancer Susceptibility Syndrome Leads to Spontaneous Pro-inflammatory Cytokine Production. EBioMedicine (2016) 0.80
Tumors STING adaptive antitumor immunity. Immunity (2014) 0.80
Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front Oncol (2016) 0.80
Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80
RIG-I-Mediated STING Upregulation Restricts Herpes Simplex Virus 1 Infection. J Virol (2016) 0.79
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget (2016) 0.79
Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine (2016) 0.79
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol (2017) 0.78
Radiation takes its Toll. Cancer Lett (2015) 0.78
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response. Sci Rep (2016) 0.78
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep (2016) 0.78
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Adv Cancer Res (2015) 0.78
Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA. MAbs (2016) 0.78
Apoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunity. Immunol Rev (2016) 0.78
cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc Natl Acad Sci U S A (2017) 0.77
Molecular basis for the specific recognition of the metazoan cyclic GMP-AMP by the innate immune adaptor protein STING. Proc Natl Acad Sci U S A (2015) 0.77
NLRC5, a promising new entry in tumor immunology. J Immunother Cancer (2016) 0.77
Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. Int J Radiat Oncol Biol Phys (2017) 0.76
STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy? Expert Rev Clin Immunol (2014) 0.76
Cell Free DNA of Tumor Origin Induces a 'Metastatic' Expression Profile in HT-29 Cancer Cell Line. PLoS One (2015) 0.76
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med (2015) 0.76
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
Involvement of GATA1 and Sp3 in the activation of the murine STING gene promoter in NIH3T3 cells. Sci Rep (2017) 0.75
The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines (Basel) (2016) 0.75
NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget (2016) 0.75
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. Oncoimmunology (2017) 0.75
Inflammatory Signals Regulate IL-15 in Response to Lymphodepletion. J Immunol (2016) 0.75
The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol (2016) 0.75
Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways. Trends Immunol (2017) 0.75
GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism. Cytokine Growth Factor Rev (2016) 0.75
Electrotransfer of plasmid DNA radiosensitizes B16F10 tumors through activation of immune response. Radiol Oncol (2017) 0.75
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75
The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele. J Immunol (2016) 0.75
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int J Mol Sci (2017) 0.75
Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene (2016) 0.75
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? Curr Breast Cancer Rep (2017) 0.75
The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. PLoS Pathog (2017) 0.75
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer (2017) 0.75
A Century of Radiation Therapy and Adaptive Immunity. Front Immunol (2017) 0.75
Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. Oral Oncol (2016) 0.75
RAD51 interconnects between DNA replication, DNA repair and immunity. Nucleic Acids Res (2017) 0.75
SENP7 Potentiates cGAS Activation by Relieving SUMO-Mediated Inhibition of Cytosolic DNA Sensing. PLoS Pathog (2017) 0.75
An RNA-Based Fluorescent Biosensor for High-Throughput Analysis of the cGAS-cGAMP-STING Pathway. Cell Chem Biol (2016) 0.75
DNA sensor cGAS-mediated immune recognition. Protein Cell (2016) 0.75
A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther (2017) 0.75
Rationale for stimulator of interferon genes-targeted cancer immunotherapy. Eur J Cancer (2017) 0.75
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer (2016) 0.75
STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy. Ann Transl Med (2016) 0.75
Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. Transl Lung Cancer Res (2017) 0.75
Immune recognition of irradiated cancer cells. Immunol Rev (2017) 0.75
TEMPORARY REMOVAL: Synthetic nanovaccines for immunotherapy. J Control Release (2017) 0.75
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling. Immunity (2017) 0.75
Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res (2017) 0.75
Cyclic GMP-AMP Ameliorates Diet-induced Metabolic Dysregulation and Regulates Proinflammatory Responses Distinctly from STING Activation. Sci Rep (2017) 0.75
Regulating STING in health and disease. J Inflamm (Lond) (2017) 0.75
Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiother Oncol (2017) 0.75
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature (2008) 10.73
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2012) 10.47
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature (2009) 9.74
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8.63
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science (2012) 7.08
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell (2004) 6.99
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 6.40
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer (2011) 4.08
Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell (2013) 3.92
Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity (2011) 3.74
The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol (2013) 3.59
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity (2012) 3.49
Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med (2012) 3.27
Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science (2013) 3.10
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell (2013) 2.97
Immune sensing of DNA. Immunity (2013) 2.96
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity (2013) 2.79
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A (2012) 2.59
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol (2012) 2.48
DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 2.41
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol (2013) 2.23
Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol (2014) 2.17
Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature (2013) 2.16
Activation of STAT6 by STING is critical for antiviral innate immunity. Cell (2011) 2.08
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell (2013) 1.82
The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity (2013) 1.80
Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med (2012) 1.68
Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol (2012) 1.65
Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol (2013) 1.44
New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med (2013) 1.35
Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood (2012) 1.08
Dissection of a type I interferon pathway in controlling bacterial intracellular infection in mice. Cell Microbiol (2011) 1.07